JP Morgan Life Sciences Private Capital

Stephen Squinto serves as chief investment officer and global head. Squinto was a co-founder of Alexion Pharmaceuticals, where he served as chief scientific officer, before becoming a venture partner at OrbiMed. Managing partner Gaurav Gupta, previously a managing director at Ascension Ventures, leads deal execution alongside him. All investment committee decisions are made within the alternatives platform of JP Morgan Asset Management.

The team leverages JP Morgan's healthcare investment-banking franchise, which advises on the majority of life-science M&A and financing transactions globally, giving the group early visibility into private companies raising capital. Squinto's operating network — built through Alexion and the rare-disease biotech community — provides another proprietary channel. Gupta's relationships from a decade of Ascension's provider-linked investing add a health-systems angle to sourcing.

Both. JP Morgan committed significant balance-sheet capital to the inaugural fund, which also raised over $500 million from external institutional limited partners. This hybrid structure means the group can invest without the strict vintage-year deployment pressures of a traditional independent venture firm, while external LP commitments provide an additional source of capital for larger rounds.

The mandate spans early- to late-stage private life-science companies. Early-stage investments include preclinical and Phase I therapeutics companies, while later-stage deployment targets companies approaching or conducting pivotal trials. The group can also invest in pre-IPO crossover rounds when the science and regulatory path are de-risked.

The group operates within JP Morgan Asset Management's alternatives division, separate from the healthcare investment-banking team and the firm's private bank. While the unit can co-invest alongside other JP Morgan-managed funds and benefits from the investment bank's deal-flow intelligence, it makes independent buy-side decisions under Squinto's investment committee. It is not a banking-supported corporate venture arm.

Squinto co-founded Alexion Pharmaceuticals in 1992 and served as its chief scientific officer through the approval and global launch of Soliris, the first drug approved for paroxysmal nocturnal hemoglobinuria. He later became chief medical officer and executive vice president. After Alexion's sale, Squinto was a venture partner at OrbiMed, a healthcare-dedicated investment firm managing over $17 billion. His 30-year arc from lab bench to blockbuster-drug commercial leader is unusual among life-science fund managers.

The group has publicly stated it focuses on biotechnology, medical devices, diagnostics, and digital health. It does not invest in healthcare services or care-delivery businesses, which fall outside its therapeutics-and-technology mandate. It also does not invest in public equities or structured credit.